Paradigm’s Executive Team has provided key leadership and expertise in a study to define genomic changes in papillary renal-cell carcinoma that has provided the most comprehensive and integrated view of gene changes for kidney cancer to date. Conventional evaluation characterizes papillary renal-cell carcinoma as a heterogeneous disease constituting various types of renal cancer; however, precious little is known about the genetic underpinnings of the various phenotypes described.
The Cancer Genome Atlas (TCGA) Research Network evaluated tumors and normal tissue from 161 patients and the analyses are reported in the November 4th issue of New England Journal of Medicine (NEJM). NEJM identifies Paradigm leadership as contributing authors to “Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma”.
The TCGA analysis utilized a number of analytic platforms including Next-Generation Sequencing (NGS) to identify copy-number alterations, mutations, gene fusions, mRNA expression levels, protein expression and methylation.
Among key findings is that the researchers defined two main papillary renal cell carcinoma groups: type 1 tumors, which were frequently marked by alterations in the MET gene pathway, and type 2 tumors, which fell into three further subtypes with variable molecular features and patient outcomes.
This type of genetic stratification by molecular pathway alterations can facilitate development of disease-specific targeted therapies. Paradigm routinely monitors patient response rates to treatment in clinical trials targeting individual cancer drivers and pathways (e.g. MET, VEGFR2, NF2, NRF2-ARE). Participating in these type of world-class studies allows Paradigm to quickly respond when genetic signatures are associated with specific treatments.
“These important findings speak to the significance of assessing the broader genomic landscape to these tumors, including mRNA expression and protein. Given there are currently no effective forms of therapy for patients with advanced metastatic papillary renal-cell carcinoma, comprehensive genomic testing can provide a mechanism to identify actionable alterations, for both standard and targeted therapies, as well as clinical trials,” stated Dr. Robert Penny, CEO Paradigm.
Paradigm is a non-profit molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit www.paradigmdx.com.
Also, follow us on Twitter @Paradigm_DX